➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Medtronic
McKesson
Merck
AstraZeneca

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Litigation Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .
Biologic Drugs cited in Belcher Pharmaceuticals, LLC v. Hospira, Inc.
The biologic drug covered by the patents cited in this case is   Start Trial .

Details for Belcher Pharmaceuticals, LLC v. Hospira, Inc. (D. Del. 2017)

Date Filed Document No. Description Snippet Link To Document
2018-12-14 118 Notice of Service 's Invalidity Contentions Regarding U.S. Patent No. 9,283,197 filed by Hospira, Inc..(Haney, Megan) (Entered…2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2019-01-07 123 Transcript Pharmaceuticals LLC v Hospira Inc., Civil Action No. 10 17-775-LPS. And we set this time to talk about …that he is a manager of patent litigation, patent 3 enforcement, patent prosecution, a whole number… to manage 3 Hospira's portfolio of patent litigation. He supervises and 4 …. He is not involved with 22 the patent prosecution. 23 And on these…Belcher has 15 with third parties about the patent. 16 Communications with the External link to document
2020-03-31 244 Opinion bioequivalent product infringes U.S. Patent No. 9,283,197 (“the ’197 Patent”) under the doctrine of equivalents…that it does not infringe the ’197 Patent and, further, that the Patent is invalid and/or unenforceable… infringe the ’197 Patent under the doctrine of equivalents, (2) the ’197 Patent is invalid as obvious…D.I. 201 at ¶¶ 3-5) II. Patent-in-Suit 8. The ’197 Patent, entitled “More Potent and …a named inventor on more than 39 U.S. patents, including patents related to drug development, formulation External link to document
2020-03-31 245 Order infringes claims 6 or 7 of U.S. Patent No. 9,283,197 (“the ’197 Patent”). 2. Defendant has…convincing evidence that claims 6 and 7 of the ’197 Patent are invalid for obviousness, that Jugal Taneja …Taneja is an improper inventor, and that the ’197 Patent is unenforceable due to inequitable conduct. Defendants…failed to prove that claims 6 and 7 of the ’197 Patent are invalid due to anticipation. 3. …2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2017-06-16 4 Patent/Trademark Report to Commissioner the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,283,197. (ceg) (Entered: 06…2017 20 April 2020 1:17-cv-00775 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2018-09-28 96 Memorandum Opinion #39;s patent, U.S. Patent No. 9,283,197 ('" 197 patent"). 1 (See id. 124) The patent discloses…characterization of its patent as a "pioneer" patent, and its argument that such a patent is entitled …; It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent specification …an appropriate solvent. See ' 197 patent, 3: 15-42. The patent also explains that the active pharmaceutical External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Boehringer Ingelheim
McKinsey
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.